Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 8

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 8
---
reatments, therapies, with ultimate goal for eventual cures utilizing the Cannabis plant and its potential for a panacea of medical relief
worldwide.

Four Winds Lake Erie, LLC – Infused
Beverage Industry

On November 22, 2021, we
acquired certain improved property located in Portland, New York from the prior owners for a total purchase price of $477,000. The property
is approximately 43 acres and has unlimited water extraction rights from the State of New York. We plan to use this property as our inroads
to the New York hemp and infused beverage markets in the future. In order to execute our business plans related to the property we must
raise funds. Along with future plans to build a “Cannabis friendly” condos & resort with a farm to food restaurant and
winery.

WEED Australia Ltd.

WEED Australia Ltd.’s
corporate strategy is to become a leader in cannabis and hemp research and development. To support this goal WEED Australia Ltd. has assembled
a highly qualified team of well-respected Ph.D.’s, scientists, researchers and business experts with the goal of establishing an
export industry. WEED Australia’s personnel has presented at several conferences regarding the use of cannabis for medical purposes
as well as for other uses. We need additional funding in order to further WEED Australia’s efforts to conduct research and development
activities in Australia.

7

WEED Israel Cannabis Ltd.

Through our subsidiary,
WEED Israel Cannabis, Ltd., we have had an arrangement with Professor Elka Touitou to conduct clinical trials on cannabis research and
studies in Israel. Professor Touitou was the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute
of Drug Research, The School of Pharmacy, HUJ, now retired but still has HUJ clinical trial & independent studies/lab privileges.
Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient
administration of drugs and development of new products. As noted above with our genomic study, there is a strong possibility that we
do our initial clinic trials in Israel due to a variety of factors, including the fact that Dr. Touitou is located in Israel, and the
fact that Israel has certain advancements in the study of cannabis that we believe would be beneficial to our clinic trial work. We need
to raise additional funds in order to conduct our planned operations in Israel.

Competitive Adv